Obesity and Diabetes
Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
Published in TB and Outbreaks Week, July 22nd, 2008
Orexigen(R) Therapeutics, Inc. (NASDAQ:OREX) announced that it has begun randomizing patients in ZB-202, a second Phase IIb clinical trial for Empatic(TM), one of the Company's two late-stage obesity product candidates. The trial is designed to build on highly encouraging safety and efficacy results from a previous Phase IIb trial of Empatic, which demonstrated robust weight loss at 48 weeks ranging from approximately 11 percent to 15 percent in obese patients completing the trial and a discontinuation rate due to adverse events that was not significantly different than placebo.
"Initiation of ZB-202 is an important milestone for our Empatic program and the final...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
More Articles from TB and Outbreaks Week
- JAMA and Archives Journals
Elevated level of certain protein associated with increased risk for diabetes - Scripps Research Institute
Scripps research scientists reveal key structure from ebola virus - Society for General Microbiology
Pandemic mutations in bird flu revealed - University of California - San Diego
Liver protein associated with type 2 diabetes in older adults - Obesity and Diabetes
National Vaccine Advisory Committee Recommends Increased Adolescent Immunization - Antibody Libraries
New research on antibody libraries from A.K. Kashyap and co-authors summarized - More from this issue of TB and Outbreaks Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
